Amsterdam-based Philips presented data from the Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial at the 2021 New Cardiovascular Horizons Conference, according to a news release.
Data presented by co-principal investigator Dr. George Adams, an interventional cardiologist at Rex Hospital (University of North Carolina, Chapel Hill) demonstrated a sustained treatment effect and a positive impact on quality of life for patients with peripheral artery disease (PAD) and critical limb ischemia (CLI) treated with the Tack dissection repair device, which Philips acquired when it bought Intact Vascular for $275 million in August 2020.
Tack, a specialized, implantable device designed to optimize the treatment of dissections in patients with PAD and CLI, provided 73.6% of patients freedom from clini…